NCT00044031View on ClinicalTrials.gov

Safety and Efficacy of G17DT Immunogen Combined With Gemcitabine vs. Gemcitabine in the Treatment of Advanced Pancreatic Carcinoma

PHASE3CompletedINTERVENTIONAL
Enrollment

394

Participants

Timeline

Start Date

February 28, 2001

Primary Completion Date

April 30, 2004

Study Completion Date

October 31, 2007

Conditions
Pancreatic Cancer
Interventions
BIOLOGICAL

G17DT Immunogen

Sponsors
All Listed Sponsors
lead

Cancer Advances Inc.

INDUSTRY

NCT00044031 - Safety and Efficacy of G17DT Immunogen Combined With Gemcitabine vs. Gemcitabine in the Treatment of Advanced Pancreatic Carcinoma | Biotech Hunter | Biotech Hunter